Department of Obstetrics and Gynecology, Del Ponte Hospital, University of Insubria, 21100 Varese, Italy.
Department of Obstetrics and Gynecology, EOC-Beata Vergine Hospital, 6850 Mendrisio, Switzerland.
Medicina (Kaunas). 2022 Jun 8;58(6):775. doi: 10.3390/medicina58060775.
To avoid complications related to mid-urethral slings (MUS), alternative procedures to treat stress urinary incontinence (SUI), such as urethral bulking agents (UBAs) have been adopted. The aim of this review is to narratively report the efficacy and safety of UBAs for SUI treatment. For this review, research from PubMed and EMBASE was performed to evaluate relevant studies that were undertaken from January 2012 to January 2022. Nineteen prospective studies were included. Several definitions of subjective and objective success were adopted. At a follow-up of <24 months, significant improvement was widely observed, even if with a heterogeneous rate of success between 32.7−90%, and a reinjection rate of 8.3−77.3%. Compared with other procedures, MUS resulted as significantly superior to UBAs but was balanced by a higher complication rate. Acute urinary retention, urinary tract infection and de novo urgency, and other complications, such as injection site rupture, urethral erosion and particle migration have been described after UBAs. SUI after UBAs treatment resulted in improvements in all studies and can be considered a safe and effective option to treat SUI. However, homogenous and longer-term data lack, limiting general recommendations. Thus, larger RCTs evaluating long-term effects are required.
为了避免与尿道中段吊带(MUS)相关的并发症,已经采用了替代治疗压力性尿失禁(SUI)的方法,例如尿道填充剂(UBAs)。本综述的目的是叙述性地报告 UBA 治疗 SUI 的疗效和安全性。 为此,我们对 PubMed 和 EMBASE 进行了研究,以评估 2012 年 1 月至 2022 年 1 月期间开展的相关研究。共纳入了 19 项前瞻性研究。采用了多种主观和客观成功的定义。在随访<24 个月时,广泛观察到明显的改善,尽管成功率在 32.7-90%之间存在差异,并且再注射率为 8.3-77.3%。与其他手术相比,MUS 明显优于 UBA,但并发症发生率更高。在 UBA 治疗后,还描述了急性尿潴留、尿路感染和新发急迫性、以及其他并发症,如注射部位破裂、尿道侵蚀和颗粒迁移。UBAs 治疗后的 SUI 所有研究均有改善,可以被认为是治疗 SUI 的安全有效的选择。然而,缺乏同质和长期的数据,限制了普遍建议。因此,需要进行更大规模的 RCT 来评估长期效果。